The estimated Net Worth of Kate Rochlin is at least $1.59 Tysiąc dollars as of 16 August 2022. Dr Rochlin owns over 5,263 units of In8 Bio stock worth over $1,593 and over the last 3 years he sold INAB stock worth over $0.
Dr has made over 1 trades of the In8 Bio stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 5,263 units of INAB stock worth $10,000 on 16 August 2022.
The largest trade he's ever made was buying 5,263 units of In8 Bio stock on 16 August 2022 worth over $10,000. On average, Dr trades about 658 units every 0 days since 2022. As of 16 August 2022 he still owns at least 5,263 units of In8 Bio stock.
You can see the complete history of Dr Rochlin stock trades at the bottom of the page.
Dr. Kate Rochlin Ph.D. is the Chief Operating Officer at In8 Bio.
Dr D is 40, he's been the Chief Operating Officer of In8 Bio since . There are 2 older and 1 younger executives at In8 Bio. The oldest executive at In8 Bio, Inc. is Dr. Lawrence S. Lamb Ph.D., 67, who is the Exec. VP, Co-Founder & Chief Scientific Officer.
Kate's mailing address filed with the SEC is C/O IN8BIO, INC., 350 5TH AVE. SUITE 5330, NEW YORK, NY, 10118.
Over the last 3 years, insiders at In8 Bio have traded over $0 worth of In8 Bio stock and bought 5,038,673 units worth $10,468,296 . The most active insiders traders include Aaron G.L.Bios Equity Partn..., Leslie W.Bios Fund Ii Nt, L... oraz Emily Transcend Partners Op.... On average, In8 Bio executives and independent directors trade stock every 32 days with the average trade being worth of $63,860. The most recent stock trade was executed by Jeremy R. Graff on 13 September 2023, trading 2,500 units of INAB stock currently worth $2,375.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
In8 Bio executives and other stock owners filed with the SEC include: